CVAC

CureVac
CVAC

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
$1.25B
EV
$820.77M
Shares Outstanding
225.16M
Beta
2.49

Wall Street View

Analyst Rating
OUTPERFORM
Analyst Target Price
$5.95
P/E 2025E
-
P/Revenue 2025E
15.71x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About CureVac N.V.

gainify
CVAC

CureVac N.V.

CVAC

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial again...

Sector

Healthcare

Industry

Biotechnology

CEO

Zehnder, Alexander

Employees

904

IPO Date

2020-08-14

Headquarters

Friedrich-Miescher-Strasse 15, Tübingen, Baden-Württemberg, 72076, Germany

gainify
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on Trustpilot
powered-by-sp

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.